Early Antiretroviral Therapy reduces the incidence of otorrhea in a randomized study of early and deferred antiretroviral therapy: Evidence from the Children with HIV Early Antiretroviral Therapy (CHER) Study
1 School of Medicine, Stony Brook University, Stony Brook, New York, USA
2 Division of Infectious Diseases, Stony Brook University, Stony Brook, New York, USA
3 Department of Paediatrics and Child Health and Children's Infectious Diseases Clinical Research Unit (KID-CRU), Tygerberg Children's Hospital and Faculty of Health Sciences, Stellenbosch University, Tygerberg, South Africa
4 School of Public Health, University of Cape Town, South Africa
5 Perinatal HIV Research Unit, University of Witwatersrand, South Africa
6 Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, University of the Witwatersrand, South Africa
BMC Research Notes 2011, 4:448 doi:10.1186/1756-0500-4-448Published: 26 October 2011
Although otorrhea occurs commonly in HIV-infected infants, there are few data. We compared the incidence of otorrhea in infants receiving early vs deferred ART in the
Data were reviewed from the start of the trial in July 2005 until 20 June 2007, when the Data Safety Monitoring Board recommended that randomization to the deferred arm should stop and that all infants in this arm be reviewed for commencing antiretroviral therapy. Infants entered the study at a median of 7.4 weeks of age. Eleven of 38 (29%) on deferred therapy and 7 of 75 (9%) in the early-therapy group developed otorrhea (risk ratio 3.1, 95% confidence interval (CI) 1.31-7.36; p = 0.01).
Early initiation of antiretroviral therapy is associated with significantly less otorrhea than when a deferred strategy is followed.